Product information
Product name | Anti-RANKL Antibody （BL-50997） |
Immunogen | Recombinant full length protein corresponding to Mouse RANKL aa 1-317 |
Host | Mouse |
Reactivity | Human,Mouse |
Applications | WB,IHC-P,ICC/IF |
Application notes | Optimal working dilutions should be determined experimentally by the investigator. Suggested starting 1:50-1:200 dilutions for most fluorescent applications. |
Clonality | Monoclonal |
Isotype | IgG1 |
Purification | Protein G purified |
Conjugate | N/A |
Applications
WB | 1/500-1/1000. Detects a band of approximately 35 kDa. |
ICC/IF | 1/100 |
Flow Cyt | N/A |
IHC-P | 1/200. |
Properties
Formulation | Liquid solution |
Storage buffer | Liquid in PBS, pH 7.4, containing 0.02% sodium azide as preservative, 1% BSA as stablizer and 50% Glycerol. |
Storage | Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze/ thaw cycle. |
Shipped at 4°C. | Shipped at 4°C. |
Background
TNFSF11 also known as RANKL, is a member of the tumor necrosis factor (TNF) cytokine family which is a ligand for osteoprotegerin and functions as a key factor for osteoclast differentiation and activation. RANKL is a polypeptide of 217 amino acids that exerts its biological activity both in a transmembrane form of about 40-45 kDa and in soluble one of 31 kDa (PMID: 15308315). RANKL induces osteoclast formation through its receptor, RANK, which transduces signals by recruiting adaptor molecules, such as the TNF receptor-associated factor (TRAF) family of proteins. RANKL was shown to be a dentritic cell survival factor and is involved in the regulation of T cell-dependent immune response. T cell activation was reported to induce expression of this gene and lead to an increase of osteoclastogenesis and bone loss. RANKL was shown to activate antiapoptotic kinase AKT/PKB through a signaling complex involving SRC kinase and tumor necrosis factor receptor-associated factor (TRAF) 6, which indicated this protein may have a role in the regulation of cell apoptosis.
